{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:33:58Z","timestamp":1792524838513,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006633","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T00:00:00Z","timestamp":1289347200000}}],"reference-count":394,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006633.pub2","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T18:46:16Z","timestamp":1288637176000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Clozapine versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2010","author":[{"given":"Claudia","family":"Asenjo Lobos","sequence":"first","affiliation":[{"name":"University of Concepcion; Victoria 232 Concepcion Regi\u00f3n del Bio Bio Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v64n0516","article-title":"Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics","volume":"64","author":"Atmaca","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1176\/appi.ajp.158.8.1305","article-title":"A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia","volume":"158","author":"Azorin","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0924-977X(99)80346-0","article-title":"Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia","volume":"9","author":"Bitter","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pnpbp.2003.09.033","article-title":"Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia","volume":"28","author":"Bitter","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0005|cit5","first-page":"S141","article-title":"Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia","volume":"3","author":"Bitter","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0006|cit6","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Martenyi F Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0007|cit7","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Martenyi F Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0008|cit8","unstructured":"Dossenbach M Slabber M Martenyi F Bartko G Bitter I Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 148"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006633.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/0924-977X(96)00012-0","article-title":"Treatment-resistant schizophrenia - clinical experience with new antipsychotics","volume":"6","author":"Bondolfi","year":"1996","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Bondolfi G Baumann P Patris M May J Billeter U Dufour H De Smedt G Lemmens P A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90593-3"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0011|cit11","unstructured":"Bondolfi G Baumann P Patris M May JP Billeter U Dufour H A randomised double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami, Florida, USA 1995"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0012|cit12","doi-asserted-by":"crossref","unstructured":"Bondolfi G Baumann P Patris M May JP Billeter U Dufour H A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia Proceedings of the Workshop on Critical Issues in the Treatment of Schizophrenia; 1995 Mar 10-12; Florence, Italy 1995 174 5","DOI":"10.1016\/0924-977X(95)90593-3"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1176\/ajp.155.4.499","article-title":"Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group","volume":"155","author":"Bondolfi","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","article-title":"The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study","volume":"23","author":"Conley","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3-4","key":"10.1002\/14651858.CD006633.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:ACLI.0000008171.90644.f8","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0020|cit17","unstructured":"Heinrich K Risperidone versus clozapine in acute schizophrenia Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France 1992 27 28"},{"issue":"Suppl 1 (Pt B)","key":"10.1002\/14651858.CD006633.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"375B","DOI":"10.1097\/00002826-199202001-00729","article-title":"Experimental comparison of the efficacy and compatibility of clozapine and risperidone in acute schizophrenia","volume":"15","author":"Heinrich","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0019|cit19","unstructured":"Heinrich K Klieser E Lehmann E Kinzler E Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1991 37 9"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0017|cit20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0278-5846(94)90029-9","article-title":"Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial","volume":"18","author":"Heinrich","year":"1994","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0021|cit21","unstructured":"Klieser E Kinzler E Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomised trial Clinical report 1991"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00004714-199502001-00008","article-title":"Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia","volume":"15","author":"Klieser","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0023|cit23","unstructured":"Klieser E Rappard F Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with acute exacerbations of schizophrenia European Psychiatry 1994 154S"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0025|cit24","unstructured":"Krakowski MI Clozapine and olanzapine in violent schizophrenics CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0024|cit25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \"high-dose\" olanzapine in refractory early-onset schizophrenia: a 12 weeks randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0027|cit27","first-page":"219","article-title":"A study of quetiapine and clozapine in treatment of the first episode schizophrenia","volume":"28","author":"Li","year":"2002","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0028|cit28","first-page":"306","article-title":"A study of quetiapine and clozapine in treatment of schizophrenia","volume":"29","author":"Li","year":"2003","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0029|cit29","first-page":"262","article-title":"A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia","volume":"17","author":"Li","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1016\/S0924-977X(03)92042-6","article-title":"Switching from clozapine to zotepine in schizophrenic patients: a randomized, single-blind controlled study","volume":"13","author":"Lin","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006633.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1016\/S0924-977X(06)70513-2","article-title":"Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up","volume":"16","author":"Lin","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006633.pub2-BIB0032|cit32","first-page":"S500","article-title":"Long-term outcome of switching from clozapine to zotepine in refractory schizophrenia: a 2-year follow-up study","volume":"15","author":"Lin","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0033|cit33","first-page":"179","article-title":"Zotepine versus clozapine: A comparison of the impact on the cognitive dysfunction syndrome in schizophrenia (a double blind trial)","volume":"28","author":"Gallhofer","year":"1995","journal-title":"Pharmacopsychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006633.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0920-9964(96)85678-7","article-title":"Cognitive dysfunction in schizophrenia: a comparison of the impact of zotepine versus clozapine on the syndrome (a double blind trial)","volume":"18","author":"Gallhofer","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-2007-979481","article-title":"Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double blind trial","volume":"30","author":"Meyer-Lindenberg","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0036|cit36","first-page":"6","article-title":"A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms","volume":"17","author":"Liu","year":"2004","journal-title":"Shandong Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/appi.ajp.161.2.364","article-title":"Do clozapine and risperidone affect social competence and problem solving?","volume":"161","author":"Bellack","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0920-9964(03)80493-0","article-title":"Tolerability of clozapine and risperidone during a twenty nine week trial","volume":"60","author":"Marder","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1176\/appi.ajp.162.5.1013","article-title":"The effects of clozapine and risperidone on spatial working memory in schizophrenia","volume":"162","author":"McGurk","year":"2005","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0040|cit40","unstructured":"McGurk SR Goldman RS Carter C Green MF Schooler N Marder SR Kane J A double-blind comparison of clozapine and risperidone on spatial working memory in treatment-resistant schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"issue":"1-2 Suppl","key":"10.1002\/14651858.CD006633.pub2-BIB0041|cit41","first-page":"238","article-title":"A double-blind comparison of clozapine and risperidone on spatial working memory in treatment resistant schizophrenia","volume":"49","author":"McGurk","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0042|cit42","first-page":"296","article-title":"Clozapine and risperidone: a 29-week randomized clinical trial","volume":"1, 2 & 3","author":"Schooler","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/oxfordjournals.schbul.a007102","article-title":"The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients","volume":"30","author":"Alphs","year":"2004","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1176\/appi.ajp.161.8.1494","article-title":"Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial","volume":"161","author":"Bourgeois","year":"2004","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4088\/JCP.v65n0513","article-title":"Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior","volume":"65","author":"Glick","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0046|cit46","first-page":"S171","article-title":"The relationship between clinical response and changes in weight for clozapine and olanzapine-treated patients","volume":"5","author":"Kane","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0924-9338(02)80116-X","article-title":"Decreasing suicide in schizophrenia: the intersept study","volume":"17","author":"Meltzer","year":"2002","journal-title":"European Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006633.pub2-BIB0051|cit48","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S0924-977X(04)80054-3","article-title":"An evidence-based approach to reducing the risk of suicide in schizophrenia","volume":"14","author":"Meltzer","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0052|cit49","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S0924-977X(03)91698-1","article-title":"Reducing risk of suicide in schizophrenia","volume":"13","author":"Meltzer","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0053|cit50","unstructured":"Meltzer HY Reducing suicidality in schizophrenia and schizoaffective disorder Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD006633.pub2-BIB0054|cit51","first-page":"47","article-title":"Suicide and schizophrenia: clozapine and the InterSePT study","volume":"60","author":"Meltzer","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0055|cit52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1749-6632.2001.tb05797.x","article-title":"Treatment of suicidality in schizophrenia","volume":"932","author":"Meltzer","year":"2001","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0048|cit53","unstructured":"Meltzer HY Alphs L Anand AR Islam MZ Potkin SG The intersept trial: reduced suicidality with clozapine treatment Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0049|cit54","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia","volume":"60","author":"Meltzer","year":"2003","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006633.pub2-BIB0050|cit55","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v64n0920","article-title":"Reducing the risk for suicide in schizophrenia and affective disorders","volume":"64","author":"Meltzer","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0056|cit56","unstructured":"Mortimer A A prospective, randomised, international, parallel group comparison of Clozaril\/Leponex vs Zyprexa in the reduction of suicidality in patients with schizophrenia or schizoaffective disorder who are at risk of suicide. National Research Register 2001"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0057|cit57","unstructured":"Mortimer A Randomised prospective parallel group comparison of clozapine vs. olanzapine in the reduction of suicidality in patients with schizophrenia\/schizoaffective disorder National Research Register 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0058|cit58","unstructured":"Novartis Pharmaceuticals Group New treatment for suicidal behavior in schizophrenia or schizoaffective disorder. International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment [CLO-8176] Archives of General Psychiatry 2003"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0006-3223(03)00178-1","article-title":"Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial","volume":"54","author":"Potkin","year":"2003","journal-title":"Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0060|cit60","first-page":"S77","article-title":"The Intersept study: reduced suicidal behavior in schizophrenic clozapine-treated patients","volume":"5","author":"Young","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/026988110401800306","article-title":"Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine","volume":"18","author":"Moresco","year":"2004","journal-title":"Journal of Psychopharmacology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0062|cit62","first-page":"194","article-title":"Effects of olanzapine versus clozapine on executive functions in schizophrenia","volume":"53","author":"Bender","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1461145705005924","article-title":"Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs clozapine","volume":"9","author":"Bender","year":"2006","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0920-9964(03)80917-9","article-title":"Effects of olanzapine versus clozapine on executive functions in schizophrenia","volume":"60","author":"Dittmann-Balcar","year":"2003","journal-title":"Schizophrenia Research"},{"issue":"1, 2","key":"10.1002\/14651858.CD006633.pub2-BIB0065|cit65","first-page":"240","article-title":"Subjective well-being under neuroleptic treatment with olanzapine versus clozapine: first results from a double-blind clinical trial using the SWN self-rating scale","volume":"49","author":"Naber","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0066|cit66","first-page":"176","article-title":"Olanzapine vs. clozapine: findings on subjective well-being from a double-blind clinical trial","volume":"53","author":"Naber","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0447.2004.00486.x","article-title":"Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia","volume":"111","author":"Naber","year":"2005","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0068|cit68","first-page":"198","article-title":"Comparison of quality of life of schizophrenic outpatients treated with risperdal or clozapine","volume":"16","author":"Ren","year":"2002","journal-title":"Chinese Mental Health Journal"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006633.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1016\/S0924-977X(06)70448-5","article-title":"Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double-blind, 18-week trial","volume":"16","author":"Sacchetti","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD006633.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0072|cit71","unstructured":"Beasley CM Beuzen JN Birkett MA Olanzapine versus clozapine: an international double-blind study in the treatment of patients with treatment-resistant schizophrenia Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA 1999"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0071|cit72","unstructured":"Beasley CM Beuzen JN Birkett MA Kiesler GM Tollefson GD Wood AJ Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0073|cit73","unstructured":"Beuzen JN Birkett M Kiesler G Wood A Olanzapine vs. clozapine in resistant schizophrenic patients - results of an international double- blind randomised clinical trial Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK 1998"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0074|cit74","unstructured":"Beuzen JN Birkett MA Kiesler GM An investigation of subgroup effects in a study of olanzapine versus clozapine in the treatment of resistant schizophrenic patients Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France 1998"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0075|cit75","unstructured":"Beuzen JN Wood AJ Kiesler GM Birkett M Tollefson GD Olanzapine vs. Clozapine: an international double-blind study in the treatment of patients with treatment-resistant schizophrenia Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0076|cit76","first-page":"s140","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"3","author":"David","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0077|cit77","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Martenyi F Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0078|cit78","unstructured":"Dossenbach M Bitter I Slabber M Pretorius J Bartko GY Banics Z Martenyi F Olanzapine versus clozapine in patients nonresponsive or intolerant to standard acceptable treatment for schizophrenia Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0079|cit79","unstructured":"Dossenbach M Slabber M Martenyi F Bartko G Bitter I Olanzapine vs. clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia World Psychiatry 1999 148"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0080|cit80","first-page":"143","article-title":"Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia","volume":"2","author":"Jean-Noel","year":"1999","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0082|cit82","first-page":"194","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder","volume":"53","author":"Bilder","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1176\/appi.ajp.159.6.1018","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder","volume":"159","author":"Bilder","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0924-977X(01)80300-X","article-title":"Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder","volume":"11","author":"Bilder","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006633.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatric Services"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0086|cit86","unstructured":"Citrome LL Volavka J Czobor P Nolan K Lieberman JA Lindenmayer J-P Sheitman BB Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0087|cit87","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer J-P McEvoy JP Lieberman JA Atypical antipsychotics and hostility in schizophrenia: a double-blind study Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0088|cit88","unstructured":"Citrome LL Volavka J Czobor P Sheitman BB Lindenmayer J-P McEvoy JP Lieberman JA Atypical antipsychotics and hostility in schizophrenia: a double-blind study Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.phrs.2004.10.013","article-title":"Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment","volume":"51","author":"Luca","year":"2005","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0091|cit91","unstructured":"Lindenmayer J-P Czobor P Volavka J Citrome LL Sheitman BB McEvoy JP Cooper TB Changes in glucose and cholesterol in schizophrenia treated with atypicals Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0092|cit92","unstructured":"Lindenmayer J-P Czobor P Volavka J Lieberman JA Citrome LL Sheitman BB McEvoy JP Effects of atypicals on the syndromal profile in treatment-resistant schizophrenia Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA 2003"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0093|cit93","unstructured":"Lindenmayer J-P Czobor P Yolayka J Lieberman JA McEvoy JP Citrome LL Sheitman BB Do atypicals change the syndrome profile in treatment-resistant schizophrenia? Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0094|cit94","unstructured":"Lindenmayer J-P Volavka J Lieberman JA Citrome LL Sheitman B McEvoy JP Cooper T Do atypicals change the syndromal profile in treatment-resistant schizophrenia? Proceedings of the155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0095|cit95","first-page":"S169","article-title":"Changes in glucose and cholesterol levels in schizophrenia patients treated with typical and atypical antipsychotics","volume":"5","author":"Lindenmayer","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006633.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"284S","DOI":"10.1016\/S0924-9338(00)94238-X","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia","volume":"15","author":"Mohr","year":"2000","journal-title":"European Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychires.2004.04.010","article-title":"Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder","volume":"39","author":"Nolan","year":"2005","journal-title":"Journal of Psychiatric Research"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000117424.05703.29","article-title":"Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"24","author":"Volavka","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0102|cit102","unstructured":"Volavka J Czobor P Sheitman B Lindenmayer J-P Citrome L McEvoy J Cooper TB Chakos M Kline JALN Clozapine, olanzapine, risperidone, and haloperidol in refractory schizophrenia Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico 2000"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0104|cit104","unstructured":"Cheine MV Wahlbeck K Tuisku K Joffe G Risperidone versus clozapine in the treatment of neuroleptic-refractory\/intolerant schizophrenia patients: a single-blind randomized trial: Preliminary report of an on-going study Nordic Journal of Psychiatry 1997 99"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0106|cit105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0278-5846(00)00118-4","article-title":"Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study","volume":"24","author":"Wahlbeck","year":"2000","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0105|cit106","first-page":"S122","article-title":"Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study","volume":"3","author":"Wahlbeck","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-9964(00)90786-2","article-title":"Risperidone versus clozapine in treatment resistant schizophrenia: a randomised pilot trial","volume":"41","author":"Wahlbeck","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0108|cit108","first-page":"143","article-title":"A double-blind randomized controlled study of olanzapine and clozapine on treatment of schizophrenia","volume":"14","author":"Wang","year":"2002","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0109|cit109","first-page":"69","article-title":"A control study of risperidone and clozapine in the treatment of the negative symptoms of schizophrenia","volume":"11","author":"Zhou","year":"2000","journal-title":"Aerospace Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00004714-200102000-00003","article-title":"Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine","volume":"21","author":"Agelink","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Allison D Cavazzoni P Beasley C Holcombe J Buse J Analysis of random glucose concentration data from patients with schizophrenia treated with typical and atypical agents during double-blind, randomized, controlled clinical trials Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany 2001","DOI":"10.1016\/S0924-977X(01)80358-8"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0924-977X(01)80358-8","article-title":"Random blood glucose levels in patients with schizophrenia treated with typical and atypical antipsychotic agents: an analysis of data from double-blind, randomized, controlled clinical trial","volume":"11","author":"Allison","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/S0924-977X(99)80054-6","article-title":"Are atypical antipsychotics less depressogenic than typical compounds?","volume":"9","author":"Altamura","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD006633.pub2-BIB0114|cit114","first-page":"47","article-title":"Risperidone vs clozapine","volume":"17","author":"Anonymous","year":"1994","journal-title":"Biological Therapies in Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-244X-6-8","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0116|cit116","unstructured":"Baumann P Billeter U Kasas A Blajev B Juvet P Souche A Bondolfi G Meylan C Dufour H Pharmacogenetic investigations about risperidone and clozapine in schizophrenic patients Proceedings of the 9th World Congress of Psychiatry; 1993 Jun 6-12; Rio de Janeiro, Brazil Switzerland 1993 76"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0117|cit117","first-page":"121S","article-title":"Treatment emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo","volume":"49","author":"Beasley","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006633.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/0924-977X(96)00012-0","article-title":"Treatment-resistant schizophrenia - clinical experience with new antipsychotics","volume":"6","author":"Bondolfi","year":"1996","journal-title":"European Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0119|cit119","first-page":"152","article-title":"The controlled investigation of risperidone and clozapine in the treatment of schizophrenia","volume":"8","author":"Cai","year":"2000","journal-title":"Health Psychology Journal"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0120|cit120","unstructured":"Lieberman JA Schneider LS McEvoy J Pariot P Stroup S Adiao J Lebowitz BD Effectiveness trials of antipsychotic drugs Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA Marathon Multimedia 2001"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0121|cit121","unstructured":"Lieberman JA Schneider LS McEvoy J Pariot P Stroup S Adiao J Lebowitz BD Effectiveness trials of antipsychotic drugs Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"issue":"10","key":"10.1002\/14651858.CD006633.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1176\/appi.ajp.160.10.1748","article-title":"Schizophrenia, VI. The CATIE Project Protocol","volume":"160","author":"Lieberman","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0124|cit123","unstructured":"McEvoy JP Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0123|cit124","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0126|cit126","first-page":"S164","article-title":"An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine","volume":"5","author":"Cavazzoni","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0127|cit127","first-page":"171","article-title":"An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine","volume":"53","author":"Cavazzoni","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0128|cit128","first-page":"143","article-title":"The curative effect comparison of risperidone and clozapine to treat recurrent schizophrenia","volume":"19","author":"Cha","year":"2002","journal-title":"Chinese Medical Journal of Metallurgical Industry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0129|cit129","first-page":"44","article-title":"A study of risperidone and clozapine in treatment of resistant schizophrenia","volume":"10","author":"Chen","year":"2002","journal-title":"Heath Psychology Journal"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0130|cit130","first-page":"298","article-title":"A control study of elderly patients with schizophrenia treated with olanzapine or clozapine","volume":"13","author":"Chen","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0131|cit131","first-page":"578","article-title":"A study of risperidone and clozapine in treatment of first episode schizophrenia","volume":"27","author":"Chen","year":"2003","journal-title":"HuaXia Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0132|cit132","first-page":"912","article-title":"A study of risperidone with haloperidol and clozapine in treatment of positive symptoms in schizophrenia","volume":"24","author":"Chen","year":"2004","journal-title":"Suzhou University Journal of Medical Science"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0133|cit133","first-page":"217","article-title":"A controlled study of olanzapine versus clozapine in schizophrenia","volume":"11","author":"Chen","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0134|cit134","first-page":"116","article-title":"A study of risperidone combination with clozapine in the treatment of the schizophrenia","volume":"13","author":"Chen","year":"2005","journal-title":"Health Psychology Journal"},{"issue":"18","key":"10.1002\/14651858.CD006633.pub2-BIB0135|cit135","first-page":"3640","article-title":"The influence of risperidone and clozapine in the quality of life of schizophrenia","volume":"8","author":"Cheng","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0136|cit136","first-page":"244","article-title":"A clinical controlled study between risperidone and clozapine in the treatment of chronic schizophrenia","volume":"12","author":"Chou","year":"1999","journal-title":"Sichuan Mental Health"},{"issue":"7","key":"10.1002\/14651858.CD006633.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0278-5846(94)90116-3","article-title":"Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis","volume":"18","author":"Chouinard","year":"1994","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"1-3","key":"10.1002\/14651858.CD006633.pub2-BIB0138|cit138","first-page":"128","article-title":"A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizophrenia","volume":"36","author":"Conley","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0139|cit139","first-page":"54","article-title":"A comparative study of the effects of risperidone, chlorpromazine and clozapine to patients with schizophrenia by the electrocardiograms","volume":"3","author":"Cui","year":"2002","journal-title":"Tianjin Pharmacy"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0140|cit140","unstructured":"Brownlee MM The CUTLASS study: a multi-centre randomised controlled trial of atypical anti-psychotic drugs in severe schizophrenia National Research Register 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0141|cit141","unstructured":"Jones PB Cost utility of the latest antipsychotics in severe schizophrenia (CUtlASS) National Research Register 2001"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0142|cit142","unstructured":"Kerwin R Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS) - a multi-centre, randomised controlled trial National Research Register 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0144|cit143","unstructured":"Lewis S Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS): a multi-centre, randomised, controlled trial National Research Register 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0145|cit144","unstructured":"Lewis S The CUTLASS study: a multi-centre randomised controlled trial of atypical anti-psychotic drugs in severe schizophrenia National Research Register 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0143|cit145","unstructured":"Lewis S Davies L Jones P Barnes T Murray R Kerwin R Taylor D Hayhurst K Markwick A Lloyd H Dunn G Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment Draft final report for NCCHTA 2003"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophrenia Bulletin"},{"issue":"17","key":"10.1002\/14651858.CD006633.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"III","DOI":"10.3310\/hta10170","article-title":"Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment","volume":"10","author":"Lewis","year":"2006","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0148|cit148","unstructured":"Marshall M Cost utility of the latest anti psychotics in severe schizophrenia (CUTLASS) National Research Register 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0149|cit149","unstructured":"Spurrell M Cost utility of the latest antipsychotics in severe schizophrenia (CUTLASS) National Research Register 2002"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0150|cit150","first-page":"396","article-title":"Comparative study on the influence of olanzapine and clozapine on efficacy and quality of life in schizophrenia","volume":"13","author":"Dai","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0151|cit151","first-page":"s140","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"3","author":"David","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/S0924-977X(99)80358-7","article-title":"Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents","volume":"9","author":"David","year":"1999","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0153|cit153","first-page":"143","article-title":"A comparative trial of olanzapine versus clozapine in the treatment of schizophrenia","volume":"12","author":"Deng","year":"2000","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0154|cit154","first-page":"309","article-title":"Control studies of increase of blood sugar induced by neo-antipsychotics","volume":"11","author":"Ding","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0155|cit155","first-page":"511","article-title":"A study of quetiapine and clozapine in treatment of chronic schizophrenia","volume":"26","author":"Du","year":"2003","journal-title":"Journal of Luzhou Medical College"},{"issue":"16","key":"10.1002\/14651858.CD006633.pub2-BIB0156|cit156","first-page":"86","article-title":"The influence of chlorpromazine, clozapine and risperidone on the cognitive function of schizophrenia","volume":"9","author":"Du","year":"2003","journal-title":"International Medicine & Health Guidance News"},{"issue":"68","key":"10.1002\/14651858.CD006633.pub2-BIB0157|cit157","first-page":"1020","article-title":"A study on the change of serum thyroxin treated with Risperdal or clozapine","volume":"11","author":"Du","year":"2004","journal-title":"Journal of Practical Medical Techniques"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0158|cit158","first-page":"8","article-title":"Effects of clozapine and risperidone on the glucose metabolism in schizophrenic patients","volume":"16","author":"Du","year":"2005","journal-title":"Qilu Journal of Medical laboratory Sciences"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0920-9964(99)00064-X","article-title":"The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia","volume":"40","author":"Earnst","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone treatment of psychosis in parkinson's disease","volume":"12","author":"Ellis","year":"2000","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0161|cit161","first-page":"131","article-title":"The effect of clozapine and risperidone on blood sugar of patients with schizophrenia","volume":"16","author":"Fan","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0162|cit162","first-page":"178","article-title":"A study of quetiapine in treatment of the dominant negative symptoms in schizophrenia","volume":"18","author":"Fang","year":"2005","journal-title":"Sichuan Mental Health"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0163|cit163","first-page":"101","article-title":"The influence of clozapine and risperidone on the weight","volume":"14","author":"Feng","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0164|cit164","first-page":"279","article-title":"Dissociation of improvement in neurocognition and negative symptomatology with olanzapine and clozapine conference abstract","volume":"1, 2 & 3","author":"Fleming","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"1, 2","key":"10.1002\/14651858.CD006633.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0920-9964(97)82526-1","article-title":"A comparison of two atypical antipsychotics in treatment resistant schizophrenia","volume":"24","author":"Flynn","year":"1997","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0166|cit166","first-page":"313","article-title":"A comparative study of quetiapine vs clozapine in the treatment of schizophrenia","volume":"11","author":"Fu","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0167|cit167","first-page":"105","article-title":"Therapeutic drug monitoring of clozapine and olanzapine. Similarities and differences","volume":"6","author":"Gaertner","year":"1999","journal-title":"Psychopharmakotherapie"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0168|cit168","first-page":"179","article-title":"Zotepine versus clozapine: A comparison of the impact on the cognitive dysfunction syndrome in schizophrenia (a double blind trial)","volume":"28","author":"Gallhofer","year":"1995","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006633.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/0924-977X(96)00010-7","article-title":"Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs","volume":"6","author":"Gallhofer","year":"1996","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0170|cit170","first-page":"561","article-title":"Prevention of weight gain, by behavioral interventions, in patients starting novel antipsychotics","volume":"31","author":"Ganguli","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0171|cit171","first-page":"221","article-title":"A study of quetiapine in the treatment of first-onset schizophrenia","volume":"13","author":"Gao","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1017\/S0033291799002639","article-title":"Effects of neuroleptic medications on speech disorganization in schizophrenia: biasing associative networks towards meaning","volume":"30","author":"Goldberg","year":"2000","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0173|cit173","unstructured":"Green AI Cannabis and schizophrenia-clozapine vs risperidone CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"9","key":"10.1002\/14651858.CD006633.pub2-BIB0174|cit174","first-page":"506","article-title":"A control study of social function improvement in schizophrenia patients with risperdal and clozapine","volume":"17","author":"Guan","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0175|cit175","first-page":"174","article-title":"Clinical controlled study of risperidone and clozapine in treatment of schizophrenia","volume":"18","author":"Guo","year":"2001","journal-title":"Journal of Xinxiang Medical College"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0176|cit176","first-page":"35","article-title":"Effect of clozapine and risperidone on interleukin-2 on schizophrenia","volume":"15","author":"Guo","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006633.pub2-BIB0177|cit177","first-page":"631","article-title":"Analysis of risperidone, clonazepam in treatment of positive symptoms in schizophrenia","volume":"27","author":"Han","year":"2005","journal-title":"Ningxia Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0178|cit178","first-page":"75","article-title":"A study of risperidone and clozapine in treatment of resistant schizophrenia","volume":"23","author":"Hang","year":"2000","journal-title":"Journal of Jining Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0179|cit179","first-page":"118","article-title":"A controlled study on hostility and side effects in clozapine and risperidone for treatment of patients with schizophrenia","volume":"22","author":"He","year":"2005","journal-title":"Journal of Xinxiang Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0180|cit180","first-page":"91","article-title":"A study of risperidone and clozapine in treatment of schizophrenia","volume":"13","author":"Hu","year":"2000","journal-title":"Journal of Handan Medical College"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0181|cit181","first-page":"428","article-title":"A study of risperidone in treatment of dominant positive symptoms in schizophrenia","volume":"14","author":"Hu","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0182|cit182","first-page":"152","article-title":"A study of risperidone and clozapine in treatment of the behaviours in schizophrenia","volume":"13","author":"Huang","year":"2001","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0183|cit183","first-page":"206","article-title":"Effectiveness of quetiapine vs clozapine in the treatment of schizophrenia","volume":"9","author":"Huang","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006633.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0185|cit185","first-page":"119","article-title":"A study of clozapine with risperidone and clozapine with sulpiride in treatment of resistant schizophrenia","volume":"14","author":"Kong","year":"2001","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0186|cit186","doi-asserted-by":"crossref","unstructured":"Konrad C Schormair C Eikelmann B Berger K Rottmann P Clozapine and risperidone in the treatment of therapy-resistant schizophrenia: a preliminary report on two ongoing clinical trials Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK 1996","DOI":"10.1016\/0924-9338(96)88849-3"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0187|cit187","first-page":"190","article-title":"Risperidone and clozapine in pharmaco-resistant schizophrenia","volume":"30","author":"Konrad","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0188|cit188","unstructured":"Konrad C Schormair C Ophaus P Knickelbein U Eikelmann B Clozapine versus risperidone in pharmaco- refractory schizophrenia: a preliminary report Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s002130050409","article-title":"IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol","volume":"133","author":"Kufferle","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0190|cit190","doi-asserted-by":"crossref","unstructured":"Lee MS Jung IK Kwak DI Clinical efficacy of clozapine in treatment-refractory schizophrenic patients Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90568-X"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0191|cit191","first-page":"169","article-title":"A controlled study on risperidone and clozapine in treatment of schizophrenia","volume":"5","author":"Lei","year":"2002","journal-title":"China Pharmacist"},{"issue":"10","key":"10.1002\/14651858.CD006633.pub2-BIB0192|cit192","first-page":"1665","article-title":"The influence of atypical antipsychotics on glucose, triglycerides and total cholesterol","volume":"4","author":"Lei","year":"2004","journal-title":"Chinese Journal of Misdiagnostics"},{"issue":"11","key":"10.1002\/14651858.CD006633.pub2-BIB0193|cit193","first-page":"653","article-title":"A comparison study on the efficacy of risperidone vs clozapin in cognition of schizophrenia","volume":"15","author":"Li","year":"2003","journal-title":"Medical Journal of Chinese People Health"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0194|cit194","first-page":"136","article-title":"A comparative study of risperidone and sulpiride in treating schizophrenia","volume":"13","author":"Li","year":"2001","journal-title":"Medical Journal of Chinese Civil Administration"},{"issue":"12","key":"10.1002\/14651858.CD006633.pub2-BIB0195|cit195","first-page":"718","article-title":"A comparison of cognitive function in the first-onset schizophrenia treated with quetiapine and clozapine","volume":"15","author":"Li","year":"2003","journal-title":"Medical Journal of Chinese People Health"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0196|cit196","first-page":"396","article-title":"A comparative study of clozapine and risperidone lead to putting on weight","volume":"12","author":"Li","year":"2004","journal-title":"Heath Psychology Journal"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0197|cit197","first-page":"193","article-title":"Controlled study of olanzapine and clozapine in the treatment of schizophrenia","volume":"15","author":"Liang","year":"2002","journal-title":"Shandong Archives of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD006633.pub2-BIB0198|cit198","first-page":"509","article-title":"A study of risperidone and clozapine in treatment of first episode schizophrenia","volume":"17","author":"Liang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0199|cit199","unstructured":"Lindenmayer JP Iskander A Apergi FS Park M Cognitive profile and soft signs in clozapine versus risperidone treatment Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0200|cit200","unstructured":"Lindenmayer JP Park M Iskander A Bark NM Smith RM Cooper TB Clozapine versus risperidone in treatment refractory state psychiatric inpatients Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 Oct 2 - May 9; New York, USA 1996"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0201|cit201","first-page":"98","article-title":"A control study of risperidone and clozapine to treating the positive symptoms of schizophrenia","volume":"12","author":"Liu","year":"1999","journal-title":"Sichuan Mental Health"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0202|cit202","first-page":"28","article-title":"A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia","volume":"14","author":"Liu","year":"2001","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0203|cit203","first-page":"152","article-title":"A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasma levels of il-2, sil-2r. an Baofu","volume":"16","author":"Liu","year":"2003","journal-title":"Sichuan Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0204|cit204","first-page":"203","article-title":"The effects of risperidone and clozapine to patients with schizophrenia's life quality","volume":"16","author":"Liu","year":"2003","journal-title":"Sichuan Mental Health"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0205|cit205","first-page":"282","article-title":"A controlled study on olanzapine and clozapine in the treatment of the acute phase of schizophrenia","volume":"16","author":"Liu","year":"2004","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0206|cit206","first-page":"293","article-title":"The influence of clozapine, risperidone and chlorpromazine on the glucose, triglycerides, total cholesterol and the weight in first episode schizophrenia","volume":"30","author":"Liu","year":"2004","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0207|cit207","first-page":"394","article-title":"A study of risperidone with clonazepam in treatment of schizophrenia","volume":"10","author":"Liu","year":"2004","journal-title":"Journal of Hainan Medical College"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0208|cit208","first-page":"13","article-title":"A comparative study of risperidone and clozapine in the treatment of refractory schizophrenia","volume":"17","author":"Liu","year":"2005","journal-title":"Journal of Heze Medical College"},{"issue":"12","key":"10.1002\/14651858.CD006633.pub2-BIB0209|cit209","first-page":"748","article-title":"A study of quetiapine with small dose of clozapine in treatment of resistant schizophrenia","volume":"17","author":"Liu","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0210|cit210","first-page":"289","article-title":"The influence of risperidone and clozapine in the quality of life of schizophrenia","volume":"17","author":"Liu","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0920-9964(96)85465-X","article-title":"Dopamine2- and serotonine2-receptor-antagonism by antipsychotics in man","volume":"18","author":"Louwerens","year":"1996","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0212|cit212","first-page":"206","article-title":"A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine","volume":"15","author":"Lu","year":"2002","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0213|cit213","first-page":"57","article-title":"Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine","volume":"20","author":"Lu","year":"2005","journal-title":"Journal of Nursing Science"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0214|cit214","first-page":"269","article-title":"The comparative study of quetiapine and clozapine in the treatment of female schizophrene","volume":"17","author":"Luo","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0215|cit215","first-page":"290","article-title":"A study of risperidone in treatment of chronic schizophrenia","volume":"7","author":"Ma","year":"1999","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0216|cit216","unstructured":"McKenna PJ An international study of improving treatment for the most severely ill with schizophrenia National Research Register 2004"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0920-9964(00)90770-9","article-title":"Change in extrapyramidal symptoms with olanzapine in comparison with other antipsychotic agents","volume":"41","author":"Meehan","year":"2000","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0218|cit218","first-page":"83","article-title":"A comparative study of social function in schizophrenic patients treated with risperidone or clozapine","volume":"11","author":"Mei","year":"2001","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0219|cit219","unstructured":"Mulqueen AW Wudarsky M Nicolson RJ Gochman P Hamburger S Lenane M Rapoport JHL Weight gain in pediatric patients on typical and atypical antipsychotics 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0220|cit220","unstructured":"Mulqueen AW Wudarsky M Nicolson RJ Gochman P Hamburger S Lenane M Rapoport JHL Weight gain in pediatric patients on typical and atypical antipsychotics Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0221|cit221","first-page":"198","article-title":"A controlled study of risperidone and clozapine both influences cognitive function of patients with schizophrenia","volume":"14","author":"Nan","year":"2001","journal-title":"Sichuan Mental Health"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0222|cit222","first-page":"181","article-title":"A study of clozapine and risperidone in treatment of schizophrenia","volume":"9","author":"Ni","year":"2001","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0223|cit223","unstructured":"Opjordsmoen S Brunsvik S Melle I Dahl A Friis S Haahr U Hustoft K Johannessen JO Larsen TK McGlashan TH Simonsen E Vaglum P A comparison between novel and traditional antipsychotics as first-line medication in early psychosis Proceedings of the 2nd International Conference on Early Psychosis; 2000 Mar 31 - Apr 2; New York, USA 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0224|cit224","doi-asserted-by":"crossref","unstructured":"Pajonk FG Tiessen F Holtzbach R Naber D Clozapine versus risperidone: an open comparative and prospective study on efficacy, tolerability and quality of life Proceedings of the 21st congress of the collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16, Glasgow 1998","DOI":"10.1016\/S0924-977X(98)80369-6"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0225|cit225","first-page":"32","article-title":"A study of olanzapine and clozapine in treatment of schizophrenia","volume":"16","author":"Pan","year":"2006","journal-title":"Zhejiang Journal of Integrated Traditional Chinese and Western Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0226|cit226","first-page":"403","article-title":"Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia","volume":"21","author":"Pao","year":"2004","journal-title":"Journal of Xinxiang Medical College"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0227|cit227","first-page":"100","article-title":"A control study of risperidone in combination with clozapine in treating refractory schizophrenia","volume":"7","author":"Peng","year":"2001","journal-title":"Journal of Modern Clinical Medical Bioengineering"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0228|cit228","first-page":"110","article-title":"Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia","volume":"4","author":"Qian","year":"2004","journal-title":"Evaluation and Analysis of Drug-use in Hospital of China"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0229|cit229","first-page":"444","article-title":"A comparative study of risperidone combining alprazolam and clozapine in the treatment of patients with schizophrenia","volume":"13","author":"Qin","year":"2005","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0230|cit230","unstructured":"Rapoport J Kumra S Jacobsen LK The spectrum of extrapyramidal symptoms in children and young adults Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA 1997"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0231|cit231","first-page":"6","article-title":"A study of risperidone and clozapine in treatment of resistant schizophrenia","volume":"35","author":"Ren","year":"2000","journal-title":"Baotou Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0232|cit232","first-page":"3","article-title":"Effects of risperidone and clozapine on life quality of schizophrenics","volume":"10","author":"Ren","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0233|cit233","first-page":"191","article-title":"Alterations of glucose metabolism under treatment with clozapine vs. amisulpride","volume":"67","author":"Rettenbacher","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0269881106069467","article-title":"Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Journal of Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-2007-1017125","article-title":"Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry","volume":"20","author":"Saletu","year":"1987","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00146965-200403000-00004","article-title":"Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments","volume":"17","author":"Scherer","year":"2004","journal-title":"Cognitive and Behavioral Neurology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0237|cit237","doi-asserted-by":"crossref","unstructured":"Schlogelhofer M Amminger GP Werneck-Rohrer S Aschauer HN Edwards J Emotion recognition deficit in first-episode schizophrenic patients and atypical antipsychotics Proceedings of the 19th European College of Neuropsychopharmacology Congress; 2006 Sep 16-20; Paris, France 2006","DOI":"10.1016\/S0924-977X(06)70545-4"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2000-7976","article-title":"A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia","volume":"33","author":"Schuld","year":"2000","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0239|cit239","first-page":"28","article-title":"The extrapyramidal side effects of risperidone","volume":"1","author":"Shao","year":"1999","journal-title":"Journal of Southeast China National Defense Medicinal Science"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0240|cit240","first-page":"195","article-title":"Cognitive effects of clozapine and olanzapine in patients with chronic schizophrenia","volume":"53","author":"Sharma","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0241|cit241","first-page":"11","article-title":"A comparison study of the blood sugar in the treatment of schizophrenic patients with risperidone, clozapine and chlorpromazine","volume":"14","author":"Sheng","year":"2003","journal-title":"Qilu Journal of Medical Laboratory Sciences"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0242|cit242","first-page":"14","article-title":"Effects of clozapine and risperidone on serum interleukin-2 and interleukin-6 of patients with first episode schizophrenia","volume":"16","author":"Sheng","year":"2005","journal-title":"Qilu Journal of Medical Laboratory Sciences"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0243|cit243","first-page":"27","article-title":"Controlled study of risperidone and clozapine in the treatment of schizophrenia","volume":"12","author":"Shi","year":"2000","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0244|cit244","first-page":"652","article-title":"A study of risperidone and clozapine in treatment of schizophrenia","volume":"15","author":"Shi","year":"2001","journal-title":"Medical Journal of Communications"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0245|cit245","unstructured":"Smith R An addition of pioglitazone or placebo to 40 patients with schizophrenia under treatment with olanzapine or clozapine Stanley Foundation Research Programs 2004"},{"issue":"1, 2","key":"10.1002\/14651858.CD006633.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0920-9964(97)82497-8","article-title":"The effect of an atypical antipsychotic (risperidone) on temporal lobe and prefrontal cortex activity in schizophrenia","volume":"24","author":"Speer","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0006-3223(96)84000-5","article-title":"D2 receptor occupancy in risperidone and clozapine-treated schizophrenics","volume":"39","author":"Su","year":"1996","journal-title":"Biological Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD006633.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archpsyc.1997.01830220102017","article-title":"D-2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients","volume":"54","author":"Su","year":"1997","journal-title":"Archives of General Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD006633.pub2-BIB0249|cit249","first-page":"1247","article-title":"A study of risperidone and clozapine in treatment of negative symptoms of resistant schizophrenia","volume":"22","author":"Sun","year":"2001","journal-title":"Journal of Qiqihar Medical"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0250|cit250","unstructured":"Swanson JW Swartz MS Van Dorn RA Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0251|cit251","unstructured":"Octavio I Tandon R Stock E Riera L Kujawa M Lam S Pans M Iwamoto T Carson W A naturalistic study of aripiprazole treatment in a general psychiatric setting Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy 2004"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","article-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)","volume":"84","author":"Tandon","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0253|cit253","unstructured":"Tandon R Stock E Riera L Kujawa M Lam S Pans M Iwamoto T A naturalistic trial with aripiprazole in a general psychiatric setting Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA 2004"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0254|cit254","first-page":"27","article-title":"A controlled study of schizophrenia treated with quetiapine and clozapine","volume":"15","author":"Tang","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0255|cit255","first-page":"167","article-title":"A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia","volume":"18","author":"Tang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0256|cit256","first-page":"303","article-title":"A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia","volume":"11","author":"Tang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0257|cit257","first-page":"261","article-title":"A study of risperidone and clozapine in treatment of schizophrenia in children","volume":"11","author":"Tian","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD006633.pub2-BIB0258|cit258","first-page":"634","article-title":"A study of clozapine and risperidone influencing on IQ and memory in schizophrenia","volume":"14","author":"Tong","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.155.4.505","article-title":"Binding of antipsychotic drugs to cortical 5-HT(2A) receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients","volume":"155","author":"Trichard","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","article-title":"Elevation of prolactin levels by atypical antipsychotics","volume":"159","author":"Turrone","year":"2002","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/j.1440-1614.2000.00813.x","article-title":"Community Treatment Orders: Relationship to clinical care, medication compliance, behavioural disturbance and readmission","volume":"34","author":"Vaughan","year":"2000","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0262|cit262","first-page":"200","article-title":"Comparative study on quality of life of schizophrenics treated with risperidone or clozapine","volume":"16","author":"Wang","year":"2002","journal-title":"Chinese Mental Health Journal"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0263|cit263","first-page":"149","article-title":"A comparative study of risperidone and clozapine on life quality of schizophrenia","volume":"16","author":"Wang","year":"2003","journal-title":"Shandong Archires of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0264|cit264","first-page":"234","article-title":"A study of risperidone and clozapine with sulpiride in treatment of schizophrenia","volume":"16","author":"Wang","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"issue":"03","key":"10.1002\/14651858.CD006633.pub2-BIB0265|cit265","first-page":"141","article-title":"A study of olanzapine and clozapine in the treatment of schizophrenia","volume":"16","author":"Wang","year":"2003","journal-title":"Shandong Archires of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0266|cit266","first-page":"167","article-title":"Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics","volume":"10","author":"Wang","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0267|cit267","first-page":"289","article-title":"Controlled study of the effect of olanzapine and clozapine on electroencephalogram of schizophrenic patients","volume":"6","author":"Wang","year":"2004","journal-title":"Journal of North China Coal Medical College"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0268|cit268","first-page":"271","article-title":"A comparative study between quetiapine and clozapine in the treatment of schizophrenia","volume":"13","author":"Wang","year":"2005","journal-title":"Heath Psychology Journal"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0269|cit269","first-page":"267","article-title":"Comparison of cognitive function and p300 potentials in first-episode schizophrenia treated with risperidone and clozapine","volume":"31","author":"Wang","year":"2005","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0270|cit270","first-page":"225","article-title":"Controlled studies of risperidone combined with clozapine in negative symptoms of schizophrenia","volume":"11","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0271|cit271","first-page":"153","article-title":"The influence of risperidone in the quality of life in schizophrenia","volume":"5","author":"Wang","year":"2005","journal-title":"Nervous Diseases and Mental Hygiene"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0272|cit272","first-page":"235","article-title":"Analysis of quetiapine in treatment of first episode schizophrenia","volume":"18","author":"Wang","year":"2005","journal-title":"Sichuan Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0273|cit273","first-page":"224","article-title":"Effectiveness of olanzapine in treatment of schizophrenia","volume":"15","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/sj.npp.1300216","article-title":"Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds","volume":"28","author":"Weickert","year":"2003","journal-title":"Neuropyschopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0275|cit275","first-page":"83","article-title":"A controlled trial of risperidone versus clozapine in the treatment of schizophrenia","volume":"8","author":"Weng","year":"1998","journal-title":"Journal of Clinical Psychological Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0276|cit276","unstructured":"Wirshing DA Perkins V Marder SR Wirshing WC Sexual side effects of atypical antipsychotic medications Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA 1999"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0277|cit277","first-page":"135","article-title":"A control study of risperidone and clozapine combination for the treatment of refractory schizophrenia","volume":"10","author":"Wu","year":"2002","journal-title":"Health Psychology Journal"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0278|cit278","first-page":"213","article-title":"A study of risperidone and clozapine in treatment of schizophrenia","volume":"16","author":"Wu","year":"2004","journal-title":"Medical Journal of Chinese People Health"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cap.1999.9.239","article-title":"Elevated prolactin in pediatric patients on typical and atypical antipsychotics","volume":"9","author":"Wudarsky","year":"1999","journal-title":"Journal of Child and Adolescent Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0280|cit280","first-page":"40","article-title":"Treatment of 31 cases of schizophrenia with quetiapine","volume":"24","author":"Xiang","year":"2005","journal-title":"Herald of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0281|cit281","first-page":"229","article-title":"A study of risperidone and clozapine in treatment of schizophrenia","volume":"10","author":"Xiao","year":"2000","journal-title":"Journal of Clinicial Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0282|cit282","first-page":"76","article-title":"A control study of risperidone and clozapine in the treatment the chronic schizophrenia","volume":"18","author":"Xie","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0283|cit283","first-page":"501","article-title":"A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia","volume":"8","author":"Xin","year":"2001","journal-title":"Herald of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0284|cit284","first-page":"132","article-title":"The effect of risperidone and clozapine treatment on serum interleukin 8, interleukin 15 in schizophrenia","volume":"13","author":"Xu","year":"2001","journal-title":"Medical Journal of Chinese Civil Administration"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0285|cit285","first-page":"227","article-title":"A study of quetiapine in treatment of schizophrenia","volume":"12","author":"Xu","year":"2002","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006633.pub2-BIB0286|cit286","first-page":"S135","article-title":"Depressive symptoms under atypical neuroleptic treatment in schizophrenia","volume":"71","author":"Yagdiran","year":"2000","journal-title":"Nervenarzt"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0924-977X(01)80272-8","article-title":"Depressive symptoms among patients with schizophrenia treated with atypical antipsychotics","volume":"11","author":"Yagdiran","year":"2001","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0288|cit288","first-page":"151-2, 159","article-title":"A controlled study of efficacy of risperidone and clozapine on treating schizophrenia whose predominant clinical features were negative symptoms","volume":"11","author":"Yang","year":"1998","journal-title":"Sichuan Mental Health"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0289|cit289","first-page":"350","article-title":"A study of risperidone and clozapine in treatment of chronic schizophrenia","volume":"14","author":"Yang","year":"2002","journal-title":"Medical Journal of Chinese Civil Administration"},{"issue":"14","key":"10.1002\/14651858.CD006633.pub2-BIB0290|cit290","first-page":"1323","article-title":"Effects of clozapine, risperidone and haloperidol on plasma leptin in first-episode schizophrenic patients","volume":"25","author":"Yang","year":"2004","journal-title":"Journal of The Fourth Military Medical University"},{"issue":"12","key":"10.1002\/14651858.CD006633.pub2-BIB0291|cit291","first-page":"1076","article-title":"The influence of antipsychotics on the ECG in schizophrenia","volume":"19","author":"Yang","year":"2004","journal-title":"Journal of Applied Clinical Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0292|cit292","first-page":"163","article-title":"A study of risperidone with clonazepam in treatment of schizophrenia","volume":"14","author":"Yang","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0293|cit293","first-page":"267","article-title":"Observation of developments of the level of serum prolactin of first-episode schizophrenia patients during the treatment","volume":"17","author":"Ye","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0294|cit294","first-page":"87","article-title":"A study of risperidone and clozapine in treatment of schizophrenia","volume":"12","author":"Yin","year":"2004","journal-title":"China Medical Engineering"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0295|cit295","first-page":"177","article-title":"An economic burden comparison of typical and atypical antipsychotic therapies for schizophrenia","volume":"35","author":"Yu","year":"2002","journal-title":"Chinese Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0296|cit296","first-page":"369","article-title":"The influence of antipsychotics on the weight and glucose","volume":"12","author":"Yuan","year":"2002","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"2B","key":"10.1002\/14651858.CD006633.pub2-BIB0297|cit297","first-page":"482","article-title":"A contrast observation of quetiapine and clozapine in affecting electroencephalogram","volume":"12","author":"Yuan","year":"2005","journal-title":"Journal of Practical Medical Techniques"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0298|cit298","first-page":"366","article-title":"A study of risperidone and clozapine in treatment of resistant patients in schizophrenia","volume":"25","author":"Yu","year":"1999","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0299|cit299","unstructured":"Zelaschi NM Rodriguez JL Gaitan S Panizzo S Sobrera A Lopez A Archuby F A follow-up study comparing clinical and endocrine effects of clozapine and risperidone Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0300|cit300","unstructured":"Zelaschi Sr NM Rodriguez Sr JL Gaitan S Palacios Vallejos ME Zieher LM The effects of the switch of conventional neuroleptics to atypical antipsychotics: a follow-up study of patients with chronic schizophrenia Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada 2006"},{"issue":"19","key":"10.1002\/14651858.CD006633.pub2-BIB0301|cit301","first-page":"2943","article-title":"Analysis of risperidone and clozapine in behavioral change in schizophrenia","volume":"6","author":"Zhan","year":"2002","journal-title":"Modern Rehabilitation"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0302|cit302","first-page":"852","article-title":"A comparison of cognitive function in the first-onset schizophrenia treated with risperidone and clozapine","volume":"23","author":"Zhang","year":"2002","journal-title":"Journal of Qiqihar Medical"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0303|cit303","first-page":"145","article-title":"Control studies of relapses between risperidone and clozapine in schizophrenia","volume":"8","author":"Zhang","year":"2002","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"14","key":"10.1002\/14651858.CD006633.pub2-BIB0304|cit304","first-page":"113","article-title":"A study of olanzapine and clozapine in EEG","volume":"10","author":"Zhang","year":"2004","journal-title":"International Medicine & Health Guidance News"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0305|cit305","first-page":"260","article-title":"A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive-compulsive symptoms","volume":"13","author":"Zhang","year":"2005","journal-title":"Heath Psychology Journal"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0306|cit306","first-page":"91","article-title":"A comparative study of social function in schizophrenia patients treated with Seroquel (quetiapine) or clozapine","volume":"18","author":"Zhang","year":"2005","journal-title":"Sichuan Mental Health"},{"issue":"12","key":"10.1002\/14651858.CD006633.pub2-BIB0307|cit307","first-page":"756","article-title":"Cost efficiency analysis of four atypical antipsychotics in treatment of schizophrenia","volume":"17","author":"Zhang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0308|cit308","first-page":"201","article-title":"Controlled study of risperidone versus clozapine in treatment of refractory schizophrenia with depressive symptoms","volume":"15","author":"Zhang","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0309|cit309","first-page":"86","article-title":"A comparative study of quetiapine and clozapine in the treatment of schizophrenia","volume":"18","author":"Zhang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0310|cit310","first-page":"290","article-title":"A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia","volume":"17","author":"Zhang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0311|cit311","first-page":"61","article-title":"40 cases of olanzapine in treatment of schizophrenia","volume":"56","author":"Zhang","year":"2005","journal-title":"Shandong Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0312|cit312","first-page":"231","article-title":"A study of quetiapine and clozapine in treatment of schizophrenia","volume":"15","author":"Zhao","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006633.pub2-BIB0313|cit313","first-page":"865","article-title":"A clinical study of clozapine and olanzapine in treatment of resistant schizophrenia","volume":"22","author":"Zheng","year":"2001","journal-title":"Journal of Qiqihar Medical"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0314|cit314","first-page":"207","article-title":"Effects of clozapine and risperidone on the glucose metabolism in first-episode schizophrenic patients","volume":"36","author":"Zheng","year":"2003","journal-title":"Chinese Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0315|cit315","first-page":"79","article-title":"A study of risperidone and clozapine in treatment of side effects on schizophrenia","volume":"13","author":"Zheng","year":"2001","journal-title":"Strait Pharmaceutical Journal"},{"issue":"6","key":"10.1002\/14651858.CD006633.pub2-BIB0316|cit316","first-page":"644","article-title":"The influence of risperidone , chlorpromazine and clozapine on ECG","volume":"23","author":"Zhong","year":"2003","journal-title":"Journal of Gannan Medical College"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0317|cit317","first-page":"395","article-title":"A control of treating chronic schizophrenia with seroquel or clozapine","volume":"6","author":"Zhou","year":"2003","journal-title":"Jiangxi Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0318|cit318","first-page":"21","article-title":"The influence of clozapine on glucose in schizophrenia","volume":"11","author":"Zhou","year":"2003","journal-title":"Liaoning Journal of Practical Diabetology"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0319|cit319","first-page":"315","article-title":"Effects of risperidone vs clozapine on blood-lipid of first-episode schizophrenia","volume":"11","author":"Zhou","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0320|cit320","first-page":"151","article-title":"A controlled study comparing drug compliance with risperidone and clozapine in treatment of schizophrenia","volume":"9","author":"Zhu","year":"1999","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0321|cit321","first-page":"324","article-title":"Study of serum IL-6 and a-IFN in the pre-and post-treatment of 68 patients with first episode schizophrenia","volume":"28","author":"Zhu","year":"2002","journal-title":"Chinese Journal of Nervous and Mental Diseases"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0322|cit322","first-page":"168","article-title":"Risperidone versus clozapine in treatment-resistant schizophrenia:a randomized controlled study","volume":"15","author":"Zhu","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"S1","key":"10.1002\/14651858.CD006633.pub2-BIB0323|cit323","first-page":"13","article-title":"15 cases of risperidone in treatment of resistant schizophrenia","volume":"6","author":"Zhu","year":"2003","journal-title":"Herald of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of a pharmacokinetic interaction between mirtazepine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacological Research"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD006633.pub2-BIB0325|cit325","first-page":"3","article-title":"Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone","volume":"60","author":"Anand","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0326|cit326","unstructured":"Byerly M Weber M Clozapine versus quetiapine for schizophrenia Stanley Foundation Research Programs 1999"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0327|cit327","unstructured":"Chengappa KN New antipsychotics-clinical trials and follow up CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0328|cit328","first-page":"181","article-title":"Horizon of a new hope: Recovery of schizophrenia in India","volume":"6","author":"Chowdhury","year":"1999","journal-title":"International Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0329|cit329","first-page":"629","article-title":"Crossover comparison of risperidone and clozapine on clinical, cognitive, and side effect measures in treatment-resistant psychosis","volume":"30","author":"Daniel","year":"1994","journal-title":"Psychopharmacology Bulletin"},{"issue":"1, 2","key":"10.1002\/14651858.CD006633.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0920-9964(95)95458-L","article-title":"Self-reported cognitive impairment predicts patient preference between risperidone and clozapine","volume":"15","author":"Daniel","year":"1995","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1176\/ajp.153.3.417","article-title":"Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study","volume":"153","author":"Daniel","year":"1996","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0332|cit332","unstructured":"Estrella MH Soria FL Gonzalez CJC Butron MAL Torres JA Escare\u00f1o RR Cost-effectiveness of clozapine vs risperidone for treatment-resistant schizophrenic patients Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0333|cit333","unstructured":"Lieberman JA Risperidone and clozapine in chronic schizophrenia CRISP database (https:\/\/www-commons.cit.nih.gov\/crisp\/index.html)"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006633.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S0924-977X(02)80431-X","article-title":"Atypical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on syllabic and language-related dichotic listening scores","volume":"12","author":"Loza","year":"2002","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0335|cit335","unstructured":"Magnuson WG Childhood onset psychotic disorders:characterization and treatment with atypical neuroleptics \/ treatment of childhood onset psychotic disorders with olanzapine or clozapine National Institutes of Health 2001"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-9964(00)90755-2","article-title":"Is olanzapine a substitute for clozapine? The effects on psychomotor performance","volume":"41","author":"Oliemeulen","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0337|cit337","unstructured":"Carpenter WT Thaker K Section 13 Psychiatry (VII. Schizophrenia) In schizophrenia: management ACP Medicine Online ( www.acpmedicine.com\/) 2002"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0339|cit339","volume-title":"Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0340|cit340","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1984"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0341|cit341","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0342|cit342","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0343|cit343","first-page":"37","article-title":"Antipsychotics - The future of schizophrenia treatment","volume":"16","author":"Beaumont","year":"2000","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1192\/bjp.157.6.853","article-title":"The social functioning scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients","volume":"157","author":"Birchwood","year":"1990","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0346|cit346","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0348|cit348","first-page":"233","article-title":"The extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00131746-200207000-00004","article-title":"Managing treatment-resistant schizophrenia: evidence from randomized clinical trials","volume":"8","author":"Citrome","year":"2002","journal-title":"Journal of psychiatric practice"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0350|cit350","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa 2000"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trial"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD006633.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0356|cit356","first-page":"222","article-title":"The hillside akathisia scale: a new rating instrument for neuroleptic-induced akathisia","volume":"25","author":"Fleischhaker","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004850-199702001-00006","article-title":"Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs","volume":"12 Suppl 1","author":"Gaebel","year":"1997","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0359|cit359","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002306","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia","author":"Gilbody","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0361|cit361","volume-title":"Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Publication no 76-338","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0362|cit362","volume-title":"Psychometric testing of the M\u00fcnchner Lebensqualit\u00e4ts Dimensionen Liste (MLDL)","author":"Heinisch","year":"1991"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0365|cit365","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009] The Cochrane Collaboration, 2009 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00606409","article-title":"Agranulocytosis during treatment with clozapine","volume":"11","author":"Id\u00e4np\u00e4\u00e4n- Heikkil\u00e4","year":"1977","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD006633.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0447.1990.tb05309.x","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"358","author":"Kane","year":"1990","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.yic.0000182114.65134.81","article-title":"Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia","volume":"21","author":"Kane","year":"2006","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0371|cit371","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD006633.pub2-BIB0372|cit372","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Molecular Psychiatry"},{"issue":"9263","key":"10.1002\/14651858.CD006633.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"9426","key":"10.1002\/14651858.CD006633.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006633.pub2-BIB0381|cit381","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006633.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007990152673864","article-title":"Focus on clozapine","volume":"17","author":"Naheed","year":"2001","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0383|cit383","first-page":"3","article-title":"Development of a dyskinetic movement scale. Early clinical drug evaluation unit","volume":"3","author":"National Institute of Mental Health","year":"1975","journal-title":"Intercom"},{"issue":"13","key":"10.1002\/14651858.CD006633.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00023210-200418130-00002","article-title":"Starting clozapine in the community: a UK perspective","volume":"18","author":"O'Brien","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0386|cit386","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Physiologica Scandinavica Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD006633.pub2-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The national institute of mental health clinical antipsychotic trial of intervention effectiveness (CATIE) project: Schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophrenia Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD006633.pub2-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"11","key":"10.1002\/14651858.CD006633.pub2-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1176\/ajp.2006.163.11.2000","article-title":"Validation of remission criteria for schizophrenia","volume":"163","author":"Os","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"9690","key":"10.1002\/14651858.CD006633.pub2-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"Os","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006633.pub2-BIB0392|cit392","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Wahlbeck","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006633.pub2-BIB0393|cit393","unstructured":"Barbato A Schizophrenia and public health Division of Mental Health and Prevention of Substance Abuse. World Health Organization 1998 1 32"},{"issue":"2","key":"10.1002\/14651858.CD006633.pub2-BIB0394|cit394","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000966","article-title":"Newer atypical antipsychotic medication versus clozapine for schizophrenia","author":"Tuunainen","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006633.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:48:11Z","timestamp":1757346491000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006633.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,11,10]]},"references-count":394,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006633.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,10]]}}}